ClinicalTrials.gg
CompletedNCT02980666Updated Feb 2, 2022Results posted

Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support

A Phase 3 interventional study of Teduglutide in Short Bowel Syndrome, sponsored by Shire. Completed at 5 sites in Japan. Open to participants aged 4 Months to 15 Years. Per ClinicalTrials.gov, last updated 2022-02-02.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
4 Months to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.

Enrollment
15th of 20
10 · median 20
Started
2017
with 1 other
Phase 3
16 of 20
none open now
Registered
12th of 20
by date
Lead sponsor
13 of 20
Shire

Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 15th largest by enrollment, is one of 2 that started in 2017, is one of 16 in phase 3, and was the 12th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About teduglutide

teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 4 Months to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing teduglutide in Short Bowel Syndrome, or all of them as a file.
02

Study summary

The purpose of this study is to determine if an investigational treatment (teduglutide) is safe and effective in Japanese children (age 4 months through 15 years of age) with SBS who are dependent on parenteral support. This study will also evaluate how teduglutide moves through the body (pharmacokinetics) and how it affects the body (pharmacodynamics).

03

Conditions studied

  • Short Bowel Syndrome

Browse trials for

04

Who can participate

Ages eligible
4 Months to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • by a parent or guardian prior to any study-related procedures
  • When applicable, informed assent (as deemed appropriate by the Institutional Review Board) by the participant prior to any study-related procedures
  • Male or female infant 4 to \<12 months corrected gestational age or child or adolescent aged 1 year through 15 years
  • Current history of SBS as a result of major intestinal resection (eg, due to necrotizing enterocolitis, midgut volvulus, intestinal atresia, or gastroschisis)
  • Short bowel syndrome that requires PN/IV support that provides at least 30% of caloric and/or fluid/electrolyte needs
  • Stable PN/IV support, defined as:

For infants 4 to \<12 months corrected gestational age: Inability to significantly reduce PN/IV support, usually associated with minimal or no advance in enteral feeds (ie, 10% or less change in PN or advance in feeds) for at least 1 month prior to and during screening, as assessed by the investigator.

For children 1 to 15 years of age:

Inability to significantly reduce PN/IV support, usually associated with minimal or no advance in enteral feeds (ie, 10% or less change in PN or advance in feeds) for at least 3 months prior to and during screening, as assessed by the investigator.

Transient instability for events such as interruption of central access or treatment of sepsis is allowed if the PN/IV support returns to within 10% of baseline prior to the event.

  • Sexually active female participants of must use medically acceptable methods of during and for 4 weeks following the last dose of product.

Exclusion criteria

Exclusion Criteria:

  • Participants who are not expected to be able to advance oral or tube feeding regimens
  • Serial transverse enteroplasty or any other bowel lengthening procedure performed within 3 months of screening
  • Known untreated intestinal obstruction contributing to feeding intolerance and inability to reduce parenteral support
  • Unstable absorption due to cystic fibrosis or other known DNA abnormalities (eg, Familial Adenomatous Polyposis, Fanconi-Bickel syndrome)
  • Severe, known dysmotility syndrome such as pseudo-obstruction or persistent, severe, active gastroschisis-related dysmotility; that is the primary contributing factor to feeding intolerance and inability to reduce parenteral support, prior to screening. Dysmotility is defined as severe if it is expected to limit the advancement of enteral feeding.
  • Evidence of clinically significant obstruction on the most recent upper GI series done within 6 months prior to screening.
  • Major GI surgical intervention including significant intestinal resection within 3 months prior to screening (insertion of feeding tube, anastomotic ulcer repair, minor intestinal resections \<=10 centimeter (cm), or endoscopic procedure is allowed)
  • Unstable cardiac disease or congenital heart disease or cyanotic disease, with the exception of participants who had undergone ventricular or atrial septal defect repair, and patent ductus arteriosus (PDA) ligation
  • History of cancer or clinically significant lymphoproliferative disease, not including resected cutaneous basal or squamous cell carcinoma, or in situ nonaggressive and surgically resected cancer. Participants with known cancer predisposition syndrome, such as juvenile polyposis or Beckwith-Wiedemann syndrome, or first degree relative with early onset of GI cancer (including hepatobiliary and pancreatic cancer) will also be excluded.
  • Pregnant or lactating female participants
  • Participation in a clinical study using an experimental drug (other than glutamine or Omegaven) within 3 months or 5.5 half-lives of the experimental drug, whichever is longer, prior to screening and for the duration of the study
  • Previous use of teduglutide or native/synthetic GLP-2
  • Previous use of glucagon-like peptide-1 analog or human growth hormone within 3 months prior to screening
  • Previous use of octreotide or dipeptidyl peptidase-4 (DPP-4) inhibitors within 3 months prior to screening
  • Participants with active Crohn's disease who had been treated with biological therapy (eg, antitumor necrosis factor [anti-TNF]) within the 6 months prior to the screening visit
  • Participants with inflammatory bowel disease (IBD) who require chronic systemic therapy that had been introduced or changed during the 3 months prior to screening
  • More than 3 serious complications of SBS (eg, documented infection-related catheter sepsis, clots, bowel obstruction, severe water-electrolyte disturbances) within 3 months prior to the screening visit
  • A serious complication that affects parenteral support requirements within 1 month prior to or during screening, excluding uncomplicated treatment of bacteremia, central line replacement/repair, or issues of similar magnitude in an otherwise stable participant
  • Body weight \< 5 kilogram (kg) at screening and baseline visits
  • Signs of active, severe, or unstable clinically significant hepatic impairment during the screening period:

For infants 4 to \<12 months corrected gestational age at least 2 of any of the following parameters:

  1. (INR) >1.5 not corrected with parenteral vitamin K
  2. count \<100×10\^3/ (microliters)mcL due to portal hypertension
  3. Presence of clinically significant gastric or esophageal varices
  4. Documented cirrhosis
  5. Persistent cholestasis defined as conjugated >4 milligram per deciliter (mg/dL) (>68 micromoles per liter [mcmol/L]) over a 2 week period

For children 1 to 15 years of age:

  1. Total bilirubin >= 2x (ULN)
  2. (AST) >= 7x ULN
  3. Alanine aminotransferase (ALT) >= 7x ULN

    • Signs of known continuous active or unstable, clinically significant renal dysfunction shown by results of an estimated below 50 milliliter per minute (mL/min)/1.73 meter (m)\^2
    • Parent(s)/guardian(s) and/or participants who are not capable of understanding or not willing to adhere to the study visit schedule and other protocol requirements
    • Unstable, clinically significant, active, untreated pancreatic or biliary disease
    • Any condition, disease, illness, or circumstance that in the investigator's opinion puts the participant at any undue risk, prevents completion of the study, or interferes with analysis of the study results.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Teduglutide

    Participants will receive teduglutide 0.05 milligram per kilogram per day (mg/kg/day) subcutaneous (SC) injection once daily for 24 weeks.

    Drug: Teduglutide

Interventions

  • 0.05 mg/kg/day SC injection once daily for 24 weeks.

06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline in Parenteral Support (PS) Volume at End of Treatment (EOT) Based on Dairy Data

    Absolute change from baseline in PS volume at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period. Here, milliliter per kilogram per day is abbreviated as mL/kg/day.

    Time frame: Baseline, EOT (up to Week 24)

  2. Percent Change From Baseline in Parenteral Support (PS) Volume at End of Treatment (EOT) Based on Dairy Data

    Percent change from baseline in PS volume at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

    Time frame: Baseline, EOT (up to Week 24)

  3. Absolute Change From Baseline in Parenteral Support (PS) Caloric Intake at End of Treatment (EOT) Based on Dairy Data

    Absolute change from baseline in PS caloric intake at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period. Here, kilo-calories per kilogram per day was abbreviated as (kcal/kg/day).

    Time frame: Baseline, EOT (up to Week 24)

  4. Percent Change From Baseline in Parenteral Support (PS) Caloric Intake at End of Treatment (EOT) Based on Dairy Data

    Percent change from baseline in PS caloric intake at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

    Time frame: Baseline, EOT (up to Week 24)

  5. Absolute Change From Baseline in Plasma Citrulline at End of Treatment (EOT)

    Absolute change from baseline in plasma citrulline at EOT (up to Week 24) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

    Time frame: Baseline, EOT (up to Week 24)

  6. Percent Change From Baseline in Plasma Citrulline at End of Treatment (EOT)

    Percent change from baseline in plasma citrulline at EOT (up to Week 24) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

    Time frame: Baseline, EOT (up to Week 24)

  7. Absolute Change From Baseline in Enteral Nutritional (EN) Volume at End of Treatment (EOT) Based on Dairy Data

    Absolute change from baseline in EN volume at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

    Time frame: Baseline, EOT (up to Week 24)

  8. Percent Change From Baseline in Enteral Nutritional (EN) Volume at End of Treatment (EOT) Based on Dairy Data

    Percent change from baseline in EN volume at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

    Time frame: Baseline, EOT (up to Week 24)

  9. Absolute Change From Baseline in Enteral Nutritional (EN) Caloric Intake at End of Treatment (EOT) Based on Dairy Data

    Absolute change from baseline in EN caloric intake at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

    Time frame: Baseline, EOT (up to Week 24)

  10. Percent Change From Baseline in Enteral Nutritional (EN) Caloric Intake at End of Treatment (EOT) Based on Dairy Data

    Percent change from baseline in EN caloric intake at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

    Time frame: Baseline, EOT (up to Week 24)

  11. Number of Participants Who Achieved At Least 20 Percent (%) Reduction in Parenteral Support (PS) Volume at Week 24

    Number of participants who achieved at least 20% reduction in PS volume at Week 24 was reported.

    Time frame: Week 24

  12. Number of Participants Who Achieved At Least 20 Percent (%) Reduction in Parenteral Support (PS) Volume at End of Treatment (EOT)

    Number of participants who achieved at least 20% reduction in PS volume at EOT (up to Week 24) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

    Time frame: EOT (up to Week 24)

  13. Number of Participants Who Achieved 100 Percent (%) Reduction in Complete Weaning of Parenteral Support (PS) Volume at End of Treatment (EOT)

    Number of participants who achieved at least 100% reduction in complete weaning of PS volume at EOT (up to Week 24) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

    Time frame: EOT (up to Week 24)

  14. Number of Participants Who Achieved Greater Than or Equal to (>=) 20 Percent (%) Reduction in Parenteral Support (PS) Volume at Week 28

    Number of participants who achieved \>= 20% reduction in PS volume at Week 28 was reported.

    Time frame: Week 28

  15. Absolute Change From End of Treatment (EOT) in Parenteral Support (PS) Volume at End of Study (EOS) Based on Dairy Data

    Absolute change from EOT (up to Week 24) in PS volume at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

    Time frame: EOT (up to Week 24), EOS (up to Week 28)

  16. Percent Change From End of Treatment (EOT) in Parenteral Support (PS) Volume at End of Study (EOS) Based on Dairy Data

    Percent change from EOT (up to Week 24) in PS volume at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

    Time frame: EOT (up to Week 24), EOS (up to Week 28)

  17. Absolute Change From End of Treatment (EOT) in Parenteral Support (PS) Caloric Intake at End of Study (EOS) Based on Dairy Data

    Absolute change from EOT (up to Week 24) in PS caloric intake at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

    Time frame: EOT (up to Week 24), EOS (up to Week 28)

  18. Percent Change From End of Treatment (EOT) in Parenteral Support (PS) Caloric Intake at End of Study (EOS) Based on Dairy Data

    Percent change from EOT (up to Week 24) in PS caloric intake at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

    Time frame: EOT (up to Week 24), EOS (up to Week 28)

  19. Absolute Change From End of Treatment (EOT) in Plasma Citrulline at End of Study (EOS)

    Absolute change from EOT (up to Week 24) in plasma citrulline at EOS (up to Week 28) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

    Time frame: EOT (up to Week 24), EOS (up to Week 28)

  20. Percent Change From End of Treatment (EOT) in Plasma Citrulline at End of Study (EOS)

    Percent change from EOT (up to Week 24) in plasma citrulline at EOS (up to Week 28) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

    Time frame: EOT (up to Week 24), EOS (up to Week 28)

  21. Absolute Change From End of Treatment (EOT) in Enteral Nutritional (EN) Volume at End of Study (EOS) Based on Dairy Data

    Absolute change from EOT (up to Week 24) in EN volume at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

    Time frame: EOT (up to Week 24), EOS (up to Week 28)

  22. Percent Change From End of Treatment (EOT) in Enteral Nutritional (EN) Volume at End of Study (EOS) Based on Dairy Data

    Percent change from EOT (up to Week 24) in EN volume at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

    Time frame: EOT (up to Week 24), EOS (up to Week 28)

  23. Absolute Change From End of Treatment (EOT) in Enteral Nutritional (EN) Caloric Intake at End of Study (EOS) Based on Dairy Data

    Absolute change from EOT (up to Week 24) in EN caloric intake at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

    Time frame: EOT (up to Week 24), EOS (up to Week 28)

  24. Percent Change From End of Treatment (EOT) in Enteral Nutritional (EN) Caloric Intake at End of Study (EOS) Based on Dairy Data

    Percent change from EOT (up to Week 24) in EN caloric intake at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

    Time frame: EOT (up to Week 24), EOS (up to Week 28)

  25. Absolute Change From Baseline in Number of Hours Per Day of Parenteral Support (PS) Usage at End of Treatment (EOT) Based on Dairy Data

    Absolute change from baseline in number of hours per day of PS Usage at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

    Time frame: Baseline, EOT (up to Week 24)

  26. Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at End of Treatment (EOT) Based on Dairy Data

    Absolute change from baseline in number of days per Week of PS usage at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

    Time frame: Baseline, EOT (up to Week 24)

  27. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An Adverse Event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as any AEs whose onset occurred, severity worsened, or intensity increased after receiving the investigational product.

    Time frame: From start of study drug administration up to EOS (up to Week 28)

  28. Change From Baseline in Body Weight for Age Z-score at Week 28

    Body weight was measured using age Z-score. A Z-score was defined as the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in body weight for age Z-score at Week 28 was reported.

    Time frame: Baseline, Week 28

  29. Change From Baseline in Height for Age Z-score at Week 28

    Height was measured using age Z-score. A Z-score was defined as the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at Week 28 was reported.

    Time frame: Baseline, Week 28

  30. Change From Baseline in Head Circumference for Age Z-score at Week 28

    Head circumference was measured using age Z-score. A Z-score was defined as the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference for age Z-score at Week 28 was reported.

    Time frame: Baseline, Week 28

  31. Number of Participants With Clinically Significant Changes in Vital Signs Reported as Treatment Emergent Adverse Events (TEAEs)

    Vital sign assessments included pulse rate, blood pressure, or body temperature. Number of participants with clinically significant changes in vital signs by the investigator were recorded as TEAEs.

    Time frame: From start of study drug administration up to EOS (up to Week 28)

  32. Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Reported as Treatment Emergent Adverse Events (TEAEs)

    12-lead ECG was performed. Any change in ECG assessments which were deemed to be clinically significant changes were recorded as TEAEs.

    Time frame: From start of study drug administration up to EOS (up to Week 28)

  33. Number of Participants With Clinically Significant Laboratory Abnormalities Reported as Treatment Emergent Adverse Events (TEAEs)

    Clinical laboratory assessments included biochemistry, hematology, coagulation, urinalysis. The number of participants with clinically significant laboratory abnormalities were reported as TEAEs.

    Time frame: From start of study drug administration up to EOS (up to Week 28)

  34. Change From Baseline in the Average Urine Output at Week 28

    Average urine output was recorded in measured volume at Week 28 was recorded.

    Time frame: Baseline, Week 28

  35. Change From Baseline in the Fecal Output at Week 28

    Change from baseline in the fecal output (Average number of stools per day) at Week 28 was recorded.

    Time frame: Baseline, Week 28

  36. Number of Participants With Positive Specific Antibodies to Teduglutide

    Number of participants with positive specific antibodies to teduglutide were used to summarize the presence of antibodies.

    Time frame: From start of study drug administration up to EOS (up to Week 28)

  37. Number of Participants With Clinically Significant Abnormal Findings in Gastrointestinal (GI) Specific Testing

    GI specific testing included colonoscopy or sigmoidoscopy, abdominal ultrasound, fecal occult blood testing, upper GI series with small bowel follow-through (UGI/SBFT). EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period. Number of participants with clinically significant abnormal findings in gastrointestinal specific testing were reported.

    Time frame: Baseline, EOT (up to Week 24)

  38. Area Under the Concentration-time Curve at Steady State (AUCtau,ss) of Teduglutide in Plasma

    Since only 2 sparse pharmacokinetics (PK) samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.

    Time frame: Baseline: Pre-dose, 1, 6 hours post-dose; Week 4: Pre-dose, 2, 4 hours post-dose

  39. Maximum Plasma Concentration at Steady-state (Cmax,ss) of Teduglutide in Plasma

    Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.

    Time frame: Baseline: Pre-dose, 1, 6 hours post-dose; Week 4: Pre-dose, 2, 4 hours post-dose

  40. Minimum Plasma Concentration at Steady-state (Cmin.ss) of Teduglutide in Plasma

    Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.

    Time frame: Baseline: Pre-dose, 1, 6 hours post-dose; Week 4: Pre-dose, 2, 4 hours post-dose

  41. Time to Reach Maximum Observed Drug Concentration (Tmax) of Teduglutide in Plasma

    Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.

    Time frame: Baseline: Pre-dose, 1, 6 hours post-dose; Week 4: Pre-dose, 2, 4 hours post-dose

  42. Terminal-Phase Half-life (t1/2) of Teduglutide in Plasma

    Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.

    Time frame: Baseline: Pre-dose, 1, 6 hours post-dose; Week 4: Pre-dose, 2, 4 hours post-dose

  43. Apparent Clearance (CL/F) of Teduglutide

    Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.

    Time frame: Baseline: Pre-dose, 1, 6 hours post-dose; Week 4: Pre-dose, 2, 4 hours post-dose

  44. Apparent Volume of Distribution (V[Lambda z]/F) of Teduglutide

    Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.

    Time frame: Baseline: Pre-dose, 1, 6 hours post-dose; Week 4: Pre-dose, 2, 4 hours post-dose

07

Results

Posted Feb 10, 2021

Participant flow

The study was conducted at 6 centers in Japan between 13 January 2017 (first participant first visit) and 21 January 2020 (last participant last visit).

Participant flow — Overall Study
MilestoneTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Started82
Completed82
Not completed00

Outcome measures

PrimaryAbsolute Change From Baseline in Parenteral Support (PS) Volume at End of Treatment (EOT) Based on Dairy Data

Absolute change from baseline in PS volume at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period. Here, milliliter per kilogram per day is abbreviated as mL/kg/day.

Time frame:
Baseline, EOT (up to Week 24)
Reported as:
Mean · mL/kg/day
Absolute Change From Baseline in Parenteral Support (PS) Volume at End of Treatment (EOT) Based on Dairy Data
mL/kg/dayTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Absolute Change From Baseline in Parenteral Support (PS) Volume at End of Treatment (EOT) Based on Dairy Data-11.8 ± 8.47-26.2 ± 13.61
PrimaryPercent Change From Baseline in Parenteral Support (PS) Volume at End of Treatment (EOT) Based on Dairy Data

Percent change from baseline in PS volume at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

Time frame:
Baseline, EOT (up to Week 24)
Reported as:
Mean · Percent Change
Percent Change From Baseline in Parenteral Support (PS) Volume at End of Treatment (EOT) Based on Dairy Data
Percent ChangeTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Percent Change From Baseline in Parenteral Support (PS) Volume at End of Treatment (EOT) Based on Dairy Data-27.7 ± 31.79-26.7 ± 15.14
PrimaryAbsolute Change From Baseline in Parenteral Support (PS) Caloric Intake at End of Treatment (EOT) Based on Dairy Data

Absolute change from baseline in PS caloric intake at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period. Here, kilo-calories per kilogram per day was abbreviated as (kcal/kg/day).

Time frame:
Baseline, EOT (up to Week 24)
Reported as:
Mean · kcal/kg/day
Absolute Change From Baseline in Parenteral Support (PS) Caloric Intake at End of Treatment (EOT) Based on Dairy Data
kcal/kg/dayTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Absolute Change From Baseline in Parenteral Support (PS) Caloric Intake at End of Treatment (EOT) Based on Dairy Data-7.2 ± 8.70-13.8 ± 3.17
PrimaryPercent Change From Baseline in Parenteral Support (PS) Caloric Intake at End of Treatment (EOT) Based on Dairy Data

Percent change from baseline in PS caloric intake at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

Time frame:
Baseline, EOT (up to Week 24)
Reported as:
Mean · Percent change
Percent Change From Baseline in Parenteral Support (PS) Caloric Intake at End of Treatment (EOT) Based on Dairy Data
Percent changeTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Percent Change From Baseline in Parenteral Support (PS) Caloric Intake at End of Treatment (EOT) Based on Dairy Data-26.2 ± 33.00-25.7 ± 2.73
PrimaryAbsolute Change From Baseline in Plasma Citrulline at End of Treatment (EOT)

Absolute change from baseline in plasma citrulline at EOT (up to Week 24) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

Time frame:
Baseline, EOT (up to Week 24)
Reported as:
Mean · Micromoles per liter (mcmol/L)
Absolute Change From Baseline in Plasma Citrulline at End of Treatment (EOT)
Micromoles per liter (mcmol/L)Total Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Absolute Change From Baseline in Plasma Citrulline at End of Treatment (EOT)3.2 ± 4.28—
PrimaryPercent Change From Baseline in Plasma Citrulline at End of Treatment (EOT)

Percent change from baseline in plasma citrulline at EOT (up to Week 24) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

Time frame:
Baseline, EOT (up to Week 24)
Reported as:
Mean · Percent change
Percent Change From Baseline in Plasma Citrulline at End of Treatment (EOT)
Percent changeTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Percent Change From Baseline in Plasma Citrulline at End of Treatment (EOT)39.2 ± 39.46—
PrimaryAbsolute Change From Baseline in Enteral Nutritional (EN) Volume at End of Treatment (EOT) Based on Dairy Data

Absolute change from baseline in EN volume at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

Time frame:
Baseline, EOT (up to Week 24)
Reported as:
Mean · mL/kg/day
Absolute Change From Baseline in Enteral Nutritional (EN) Volume at End of Treatment (EOT) Based on Dairy Data
mL/kg/dayTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Absolute Change From Baseline in Enteral Nutritional (EN) Volume at End of Treatment (EOT) Based on Dairy Data1.0 ± 7.140.6 ± 2.15
PrimaryPercent Change From Baseline in Enteral Nutritional (EN) Volume at End of Treatment (EOT) Based on Dairy Data

Percent change from baseline in EN volume at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

Time frame:
Baseline, EOT (up to Week 24)
Reported as:
Mean · Percent change
Percent Change From Baseline in Enteral Nutritional (EN) Volume at End of Treatment (EOT) Based on Dairy Data
Percent changeTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Percent Change From Baseline in Enteral Nutritional (EN) Volume at End of Treatment (EOT) Based on Dairy Data53.1 ± 111.01-23.2 ± 36.89
PrimaryAbsolute Change From Baseline in Enteral Nutritional (EN) Caloric Intake at End of Treatment (EOT) Based on Dairy Data

Absolute change from baseline in EN caloric intake at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

Time frame:
Baseline, EOT (up to Week 24)
Reported as:
Mean · kcal/kg/day
Absolute Change From Baseline in Enteral Nutritional (EN) Caloric Intake at End of Treatment (EOT) Based on Dairy Data
kcal/kg/dayTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Absolute Change From Baseline in Enteral Nutritional (EN) Caloric Intake at End of Treatment (EOT) Based on Dairy Data0.8 ± 5.600.3 ± 1.03
PrimaryPercent Change From Baseline in Enteral Nutritional (EN) Caloric Intake at End of Treatment (EOT) Based on Dairy Data

Percent change from baseline in EN caloric intake at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

Time frame:
Baseline, EOT (up to Week 24)
Reported as:
Mean · Percent change
Percent Change From Baseline in Enteral Nutritional (EN) Caloric Intake at End of Treatment (EOT) Based on Dairy Data
Percent changeTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Percent Change From Baseline in Enteral Nutritional (EN) Caloric Intake at End of Treatment (EOT) Based on Dairy Data56.8 ± 117.88-24.2 ± 38.06
PrimaryNumber of Participants Who Achieved At Least 20 Percent (%) Reduction in Parenteral Support (PS) Volume at Week 24

Number of participants who achieved at least 20% reduction in PS volume at Week 24 was reported.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants Who Achieved At Least 20 Percent (%) Reduction in Parenteral Support (PS) Volume at Week 24
ParticipantsTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Number of Participants Who Achieved At Least 20 Percent (%) Reduction in Parenteral Support (PS) Volume at Week 2441
PrimaryNumber of Participants Who Achieved At Least 20 Percent (%) Reduction in Parenteral Support (PS) Volume at End of Treatment (EOT)

Number of participants who achieved at least 20% reduction in PS volume at EOT (up to Week 24) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

Time frame:
EOT (up to Week 24)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved At Least 20 Percent (%) Reduction in Parenteral Support (PS) Volume at End of Treatment (EOT)
ParticipantsTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Number of Participants Who Achieved At Least 20 Percent (%) Reduction in Parenteral Support (PS) Volume at End of Treatment (EOT)41
PrimaryNumber of Participants Who Achieved 100 Percent (%) Reduction in Complete Weaning of Parenteral Support (PS) Volume at End of Treatment (EOT)

Number of participants who achieved at least 100% reduction in complete weaning of PS volume at EOT (up to Week 24) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

Time frame:
EOT (up to Week 24)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved 100 Percent (%) Reduction in Complete Weaning of Parenteral Support (PS) Volume at End of Treatment (EOT)
ParticipantsTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Number of Participants Who Achieved 100 Percent (%) Reduction in Complete Weaning of Parenteral Support (PS) Volume at End of Treatment (EOT)10
PrimaryNumber of Participants Who Achieved Greater Than or Equal to (>=) 20 Percent (%) Reduction in Parenteral Support (PS) Volume at Week 28

Number of participants who achieved \>= 20% reduction in PS volume at Week 28 was reported.

Time frame:
Week 28
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Greater Than or Equal to (>=) 20 Percent (%) Reduction in Parenteral Support (PS) Volume at Week 28
ParticipantsTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Number of Participants Who Achieved Greater Than or Equal to (>=) 20 Percent (%) Reduction in Parenteral Support (PS) Volume at Week 2831
PrimaryAbsolute Change From End of Treatment (EOT) in Parenteral Support (PS) Volume at End of Study (EOS) Based on Dairy Data

Absolute change from EOT (up to Week 24) in PS volume at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

Time frame:
EOT (up to Week 24), EOS (up to Week 28)
Reported as:
Mean · mL/kg/day
Absolute Change From End of Treatment (EOT) in Parenteral Support (PS) Volume at End of Study (EOS) Based on Dairy Data
mL/kg/dayTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Absolute Change From End of Treatment (EOT) in Parenteral Support (PS) Volume at End of Study (EOS) Based on Dairy Data3.9 ± 7.06-3.8 ± 0.67
PrimaryPercent Change From End of Treatment (EOT) in Parenteral Support (PS) Volume at End of Study (EOS) Based on Dairy Data

Percent change from EOT (up to Week 24) in PS volume at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

Time frame:
EOT (up to Week 24), EOS (up to Week 28)
Reported as:
Mean · Percent change
Percent Change From End of Treatment (EOT) in Parenteral Support (PS) Volume at End of Study (EOS) Based on Dairy Data
Percent changeTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Percent Change From End of Treatment (EOT) in Parenteral Support (PS) Volume at End of Study (EOS) Based on Dairy Data9.8 ± 19.59-5.5 ± 2.35
PrimaryAbsolute Change From End of Treatment (EOT) in Parenteral Support (PS) Caloric Intake at End of Study (EOS) Based on Dairy Data

Absolute change from EOT (up to Week 24) in PS caloric intake at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

Time frame:
EOT (up to Week 24), EOS (up to Week 28)
Reported as:
Mean · kcal/kg/day
Absolute Change From End of Treatment (EOT) in Parenteral Support (PS) Caloric Intake at End of Study (EOS) Based on Dairy Data
kcal/kg/dayTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Absolute Change From End of Treatment (EOT) in Parenteral Support (PS) Caloric Intake at End of Study (EOS) Based on Dairy Data0.5 ± 6.16-4.0 ± 1.38
PrimaryPercent Change From End of Treatment (EOT) in Parenteral Support (PS) Caloric Intake at End of Study (EOS) Based on Dairy Data

Percent change from EOT (up to Week 24) in PS caloric intake at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

Time frame:
EOT (up to Week 24), EOS (up to Week 28)
Reported as:
Mean · Percent change
Percent Change From End of Treatment (EOT) in Parenteral Support (PS) Caloric Intake at End of Study (EOS) Based on Dairy Data
Percent changeTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Percent Change From End of Treatment (EOT) in Parenteral Support (PS) Caloric Intake at End of Study (EOS) Based on Dairy Data3.5 ± 19.17-10.3 ± 4.40
PrimaryAbsolute Change From End of Treatment (EOT) in Plasma Citrulline at End of Study (EOS)

Absolute change from EOT (up to Week 24) in plasma citrulline at EOS (up to Week 28) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

Time frame:
EOT (up to Week 24), EOS (up to Week 28)
Reported as:
Mean · Micromoles (mcM)
Absolute Change From End of Treatment (EOT) in Plasma Citrulline at End of Study (EOS)
Micromoles (mcM)Total Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Absolute Change From End of Treatment (EOT) in Plasma Citrulline at End of Study (EOS)-2.9 ± 2.87—
PrimaryPercent Change From End of Treatment (EOT) in Plasma Citrulline at End of Study (EOS)

Percent change from EOT (up to Week 24) in plasma citrulline at EOS (up to Week 28) was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

Time frame:
EOT (up to Week 24), EOS (up to Week 28)
Reported as:
Mean · Percent change
Percent Change From End of Treatment (EOT) in Plasma Citrulline at End of Study (EOS)
Percent changeTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Percent Change From End of Treatment (EOT) in Plasma Citrulline at End of Study (EOS)-20.0 ± 24.16—
PrimaryAbsolute Change From End of Treatment (EOT) in Enteral Nutritional (EN) Volume at End of Study (EOS) Based on Dairy Data

Absolute change from EOT (up to Week 24) in EN volume at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

Time frame:
EOT (up to Week 24), EOS (up to Week 28)
Reported as:
Mean · mL/kg/day
Absolute Change From End of Treatment (EOT) in Enteral Nutritional (EN) Volume at End of Study (EOS) Based on Dairy Data
mL/kg/dayTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Absolute Change From End of Treatment (EOT) in Enteral Nutritional (EN) Volume at End of Study (EOS) Based on Dairy Data-1.5 ± 3.24-2.8 ± 3.98
PrimaryPercent Change From End of Treatment (EOT) in Enteral Nutritional (EN) Volume at End of Study (EOS) Based on Dairy Data

Percent change from EOT (up to Week 24) in EN volume at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

Time frame:
EOT (up to Week 24), EOS (up to Week 28)
Reported as:
Mean · Percent change
Percent Change From End of Treatment (EOT) in Enteral Nutritional (EN) Volume at End of Study (EOS) Based on Dairy Data
Percent changeTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Percent Change From End of Treatment (EOT) in Enteral Nutritional (EN) Volume at End of Study (EOS) Based on Dairy Data-22.1 ± 28.06-1.4 ± 8.25
PrimaryAbsolute Change From End of Treatment (EOT) in Enteral Nutritional (EN) Caloric Intake at End of Study (EOS) Based on Dairy Data

Absolute change from EOT (up to Week 24) in EN caloric intake at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

Time frame:
EOT (up to Week 24), EOS (up to Week 28)
Reported as:
Mean · kcal/kg/day
Absolute Change From End of Treatment (EOT) in Enteral Nutritional (EN) Caloric Intake at End of Study (EOS) Based on Dairy Data
kcal/kg/dayTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Absolute Change From End of Treatment (EOT) in Enteral Nutritional (EN) Caloric Intake at End of Study (EOS) Based on Dairy Data-1.1 ± 2.64-1.4 ± 1.97
PrimaryPercent Change From End of Treatment (EOT) in Enteral Nutritional (EN) Caloric Intake at End of Study (EOS) Based on Dairy Data

Percent change from EOT (up to Week 24) in EN caloric intake at EOS (up to Week 28) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

Time frame:
EOT (up to Week 24), EOS (up to Week 28)
Reported as:
Mean · Percent change
Percent Change From End of Treatment (EOT) in Enteral Nutritional (EN) Caloric Intake at End of Study (EOS) Based on Dairy Data
Percent changeTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Percent Change From End of Treatment (EOT) in Enteral Nutritional (EN) Caloric Intake at End of Study (EOS) Based on Dairy Data-22.1 ± 28.16-3.0 ± 6.03
PrimaryAbsolute Change From Baseline in Number of Hours Per Day of Parenteral Support (PS) Usage at End of Treatment (EOT) Based on Dairy Data

Absolute change from baseline in number of hours per day of PS Usage at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

Time frame:
Baseline, EOT (up to Week 24)
Reported as:
Mean · Hours per day (hours/day)
Absolute Change From Baseline in Number of Hours Per Day of Parenteral Support (PS) Usage at End of Treatment (EOT) Based on Dairy Data
Hours per day (hours/day)Total Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Absolute Change From Baseline in Number of Hours Per Day of Parenteral Support (PS) Usage at End of Treatment (EOT) Based on Dairy Data-2.1 ± 4.160.0 ± 0.00
PrimaryAbsolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at End of Treatment (EOT) Based on Dairy Data

Absolute change from baseline in number of days per Week of PS usage at EOT (up to Week 24) based on dairy data was reported. EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period.

Time frame:
Baseline, EOT (up to Week 24)
Reported as:
Mean · Days per week
Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at End of Treatment (EOT) Based on Dairy Data
Days per weekTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at End of Treatment (EOT) Based on Dairy Data-0.9 ± 2.470.0 ± 0.00
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An Adverse Event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as any AEs whose onset occurred, severity worsened, or intensity increased after receiving the investigational product.

Time frame:
From start of study drug administration up to EOS (up to Week 28)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Number of Participants With Treatment-emergent Adverse Events (TEAEs)82
PrimaryChange From Baseline in Body Weight for Age Z-score at Week 28

Body weight was measured using age Z-score. A Z-score was defined as the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in body weight for age Z-score at Week 28 was reported.

Time frame:
Baseline, Week 28
Reported as:
Mean · Z-score
Change From Baseline in Body Weight for Age Z-score at Week 28
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in Body Weight for Age Z-score at Week 280.177 ± 0.36252.332 ± 1.1503
PrimaryChange From Baseline in Height for Age Z-score at Week 28

Height was measured using age Z-score. A Z-score was defined as the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at Week 28 was reported.

Time frame:
Baseline, Week 28
Reported as:
Mean · Z-score
Change From Baseline in Height for Age Z-score at Week 28
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in Height for Age Z-score at Week 280.024 ± 0.48411.056 ± 0.6968
PrimaryChange From Baseline in Head Circumference for Age Z-score at Week 28

Head circumference was measured using age Z-score. A Z-score was defined as the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference for age Z-score at Week 28 was reported.

Time frame:
Baseline, Week 28
Reported as:
Mean · Z-score
Change From Baseline in Head Circumference for Age Z-score at Week 28
Z-scoreTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in Head Circumference for Age Z-score at Week 28—1.559 ± 0.6116
PrimaryNumber of Participants With Clinically Significant Changes in Vital Signs Reported as Treatment Emergent Adverse Events (TEAEs)

Vital sign assessments included pulse rate, blood pressure, or body temperature. Number of participants with clinically significant changes in vital signs by the investigator were recorded as TEAEs.

Time frame:
From start of study drug administration up to EOS (up to Week 28)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Signs Reported as Treatment Emergent Adverse Events (TEAEs)
ParticipantsTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Number of Participants With Clinically Significant Changes in Vital Signs Reported as Treatment Emergent Adverse Events (TEAEs)00
PrimaryNumber of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Reported as Treatment Emergent Adverse Events (TEAEs)

12-lead ECG was performed. Any change in ECG assessments which were deemed to be clinically significant changes were recorded as TEAEs.

Time frame:
From start of study drug administration up to EOS (up to Week 28)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Reported as Treatment Emergent Adverse Events (TEAEs)
ParticipantsTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Reported as Treatment Emergent Adverse Events (TEAEs)00
PrimaryNumber of Participants With Clinically Significant Laboratory Abnormalities Reported as Treatment Emergent Adverse Events (TEAEs)

Clinical laboratory assessments included biochemistry, hematology, coagulation, urinalysis. The number of participants with clinically significant laboratory abnormalities were reported as TEAEs.

Time frame:
From start of study drug administration up to EOS (up to Week 28)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Reported as Treatment Emergent Adverse Events (TEAEs)
ParticipantsTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Number of Participants With Clinically Significant Laboratory Abnormalities Reported as Treatment Emergent Adverse Events (TEAEs)00
PrimaryChange From Baseline in the Average Urine Output at Week 28

Average urine output was recorded in measured volume at Week 28 was recorded.

Time frame:
Baseline, Week 28
Reported as:
Mean · mL/kg/day
Change From Baseline in the Average Urine Output at Week 28
mL/kg/dayTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in the Average Urine Output at Week 28-22.317 ± 34.8252-48.879 ± NA
PrimaryChange From Baseline in the Fecal Output at Week 28

Change from baseline in the fecal output (Average number of stools per day) at Week 28 was recorded.

Time frame:
Baseline, Week 28
Reported as:
Mean · Average number of stools per day
Change From Baseline in the Fecal Output at Week 28
Average number of stools per dayTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Change From Baseline in the Fecal Output at Week 28-0.64 ± 1.5472.50 ± NA
PrimaryNumber of Participants With Positive Specific Antibodies to Teduglutide

Number of participants with positive specific antibodies to teduglutide were used to summarize the presence of antibodies.

Time frame:
From start of study drug administration up to EOS (up to Week 28)
Reported as:
Count of participants · Participants
Number of Participants With Positive Specific Antibodies to Teduglutide
ParticipantsTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Number of Participants With Positive Specific Antibodies to Teduglutide12
PrimaryNumber of Participants With Clinically Significant Abnormal Findings in Gastrointestinal (GI) Specific Testing

GI specific testing included colonoscopy or sigmoidoscopy, abdominal ultrasound, fecal occult blood testing, upper GI series with small bowel follow-through (UGI/SBFT). EOT was defined as the last available measurement after the date of first dose during the 24-week treatment period. Number of participants with clinically significant abnormal findings in gastrointestinal specific testing were reported.

Time frame:
Baseline, EOT (up to Week 24)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Findings in Gastrointestinal (GI) Specific Testing
ParticipantsTotal Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Number of Participants With Clinically Significant Abnormal Findings in Gastrointestinal (GI) Specific Testing0—
PrimaryArea Under the Concentration-time Curve at Steady State (AUCtau,ss) of Teduglutide in Plasma

Since only 2 sparse pharmacokinetics (PK) samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.

Time frame:
Baseline: Pre-dose, 1, 6 hours post-dose; Week 4: Pre-dose, 2, 4 hours post-dose

No measurements were reported for this outcome.

PrimaryMaximum Plasma Concentration at Steady-state (Cmax,ss) of Teduglutide in Plasma

Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.

Time frame:
Baseline: Pre-dose, 1, 6 hours post-dose; Week 4: Pre-dose, 2, 4 hours post-dose

No measurements were reported for this outcome.

PrimaryMinimum Plasma Concentration at Steady-state (Cmin.ss) of Teduglutide in Plasma

Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.

Time frame:
Baseline: Pre-dose, 1, 6 hours post-dose; Week 4: Pre-dose, 2, 4 hours post-dose

No measurements were reported for this outcome.

PrimaryTime to Reach Maximum Observed Drug Concentration (Tmax) of Teduglutide in Plasma

Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.

Time frame:
Baseline: Pre-dose, 1, 6 hours post-dose; Week 4: Pre-dose, 2, 4 hours post-dose

No measurements were reported for this outcome.

PrimaryTerminal-Phase Half-life (t1/2) of Teduglutide in Plasma

Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.

Time frame:
Baseline: Pre-dose, 1, 6 hours post-dose; Week 4: Pre-dose, 2, 4 hours post-dose

No measurements were reported for this outcome.

PrimaryApparent Clearance (CL/F) of Teduglutide

Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.

Time frame:
Baseline: Pre-dose, 1, 6 hours post-dose; Week 4: Pre-dose, 2, 4 hours post-dose

No measurements were reported for this outcome.

PrimaryApparent Volume of Distribution (V[Lambda z]/F) of Teduglutide

Since only 2 sparse PK samples were collected during the study, PK parameters were not estimated and analyzed using this study samples. Therefore, no PK parameters were reported in this study.

Time frame:
Baseline: Pre-dose, 1, 6 hours post-dose; Week 4: Pre-dose, 2, 4 hours post-dose

No measurements were reported for this outcome.

Adverse events

Collected over From start of study drug administration up to end of the study (up to Week 28). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Total Children (Aged: 1 - 15 Years)0/8 (0%)6/8 (75%)8/8 (100%)
Infants (Corrected Gestational Age: 4 to < 12 Months)0/2 (0%)2/2 (100%)1/2 (50%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventTotal Children (Aged: 1 - 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
PyrexiaGeneral disorders0/82/2
Device related infectionInfections and infestations3/81/2
Upper respiratory tract infectionInfections and infestations0/81/2
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders0/81/2
EnterocolitisGastrointestinal disorders2/80/2
Medical device site infectionInfections and infestations2/80/2
Abdominal painGastrointestinal disorders1/80/2
Anaphylactic reactionImmune system disorders1/80/2
Adenovirus infectionInfections and infestations1/80/2
GastroenteritisInfections and infestations1/80/2
Most frequent other events
Showing 10 of 44
Most frequent other events
EventTotal Children (Aged: 1 - 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)
Viral upper respiratory tract infectionInfections and infestations6/81/2
EnterocolitisGastrointestinal disorders0/81/2
Otitis mediaInfections and infestations0/81/2
Vaccination complicationInjury, poisoning and procedural complications0/81/2
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders0/81/2
Dermatitis contactSkin and subcutaneous tissue disorders0/81/2
Dermatitis diaperSkin and subcutaneous tissue disorders1/81/2
Dry skinSkin and subcutaneous tissue disorders2/81/2
RashSkin and subcutaneous tissue disorders4/80/2
Injection site erythemaGeneral disorders3/80/2

Baseline characteristics

Intention-to-treat (ITT) population consisted of all participants who were enrolled into the study and met all eligible criteria for the study.

Age, Customized
Age, Customized(Participants)Total Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)Total
Count of participants8210
Sex: Female, Male
Sex: Female, Male(Participants)Total Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)Total
Female112
Male718
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Total Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)Total
Hispanic or Latino000
Not Hispanic or Latino8210
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Total Children (Aged: 1 to 15 Years)Infants (Corrected Gestational Age: 4 to < 12 Months)Total
American Indian or Alaska Native000
Asian8210
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

5 sites
  • Kyushu University Hospital
    Fukuoka-shi, Fukuoka-ken 812-8582, Japan
  • Tsukuba University Hospital
    Tsukuba, Ibaraki-Ken 305-8576, Japan
  • Kagoshima University
    Kagoshima-shi, Kagoshima-Ken 890-8520, Japan
  • Tohoku University Hospital
    Sendai-shi, Miyagi-Ken 980-8574, Japan
  • Showa University
    Shinagawa-ku, Tokyo-To 142-8555, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites, ...).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Jan 2020, 36 months.

Results were first posted in Feb 2021, 1 year after primary completion.

Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 36 months is close to that.

Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2016
First posted
Dec 2, 2016
StartActual
Jan 13, 2017
Primary completionActual
Jan 21, 2020
CompletionActual
Jan 21, 2020
Results first posted
Feb 10, 2021
Last update
Feb 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02980666
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Dec 2, 2016
Start date
Jan 13, 2017
Primary completion
Jan 21, 2020
Completion
Jan 21, 2020
Results posted
Feb 10, 2021
Last update
Feb 2, 2022

Study contacts

Study Director
study director · Shire

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion